Garuda - Garba Rujukan Digital

p-Index From 2020 - 2025

2.33

P-Index

This Author published in this journals

All Journal Journal of the Medical Sciences (Berkala Ilmu Kedokteran) Indonesian Journal of Urology Paediatrica Indonesiana Indonesian Journal of Cancer Berita Kedokteran Masyarakat Indonesian Journal of Biomedicine and Clinical Sciences

Indrawarman Soeroharjo

Division Of Urology, Department Of Internal Medicine, Faculty Of Medicine, Public Health And Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia

Author-ID : 384151

Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Nursing Public Health

Published : 17 Documents Claim Missing Document

Claim Missing Document

Articles

Title

mRNA expression of CYP17A1, CYP11A1, CYP19A1, HSD3B1 and AKR1C2 in metastatic and non-metastatic prostate cancer patients Indrawarman Soerohardjo; Muhammad Puteh Mauny; Alharsya Franklyn Ruckle; Ahmad Zulfan; Raden Danarto; Didik Setyo Heriyanto
Journal of the Medical Sciences (Berkala Ilmu Kedokteran) Vol 50, No 4 (2018)
Publisher : Journal of the Medical Sciences (Berkala Ilmu Kedokteran)

The progression of prostate cancer (PCa) mainly occurs caused by androgens. There is a linkbetween intratumoral steroidogenesis and castration-resistant prostate cancer. This studyaimed to determine the mRNA expression of various steroidogenic enzymes (CYP17A1,CYP11A1, CYP19A1, HSD3B1, and AKR1C2) in metastatic and non-metastatic prostatecancer patients. This study was conducted at the Anatomical Pathology Laboratory andUrologi Division, Department of Surgery, Faculty of Medicine, Public Health and Nursing,Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta from September-November 2017. Samples were taken from 30 paraffin blocks with adenocarcinoma ofprostate, stained with hematoxylin-eosin (HE) and then classified into metastatic and nonmetastaticgroups. Samples then underwent deparaffinization procedure and examinationof mRNA expression of CYP17A1, CYP11A1, CYP19A1, HSD3B1, AKR1C2 genes usingReal-Time PCR. The mean mRNA expressions of CYP11A1, CYP17A1, CYP19A1,HSD3B1, and AKR1C2 genes in the metastatic adenocarcinoma prostate group were 7.08,10.11, 3.94, 4.84 and 3.58, respectively. In the non-metastatic group, the mean mRNAexpressions of CYP11A1, CYP17A1, CYP19A1, HSD3B1, and AKR1C2 genes were 4.62,9.45, 3.46, 2.68 and 4.92, respectively. The mean of mRNA expression of CYP11A1,CYP17A1, CYP19A1, and HSD3B1 genes were higher in the metastatic group than nonmetastaticadenocarcinoma prostate group. However, it was not statistically significant(p>0.05). The highest mRNA expression of steroidogenic enzymes was the CYP17A1gene. In conclusion, the mRNA expressions of CYP17A1, CYP11A1, CYP19A1, HSD3B1were higher in the metastatic prostate cancer patients compared to that in non-metastaticprostate cancer patients but statistically not significant.

Diagnosis value of prostate specific antigen density (PSAD) and prostate specific antigen (PSA) in bone metastases of prostate cancer among Indonesian population Ahmad Zulfan Hendri; Andy Zulfiqqar; Indrawarman soeharjo; Raden Danarto
Journal of the Medical Sciences (Berkala Ilmu Kedokteran) Vol 52, No 2 (2020)
Publisher : Journal of the Medical Sciences (Berkala Ilmu Kedokteran)

Cancer prostate (PCa) is currently reported as the most diagnosed cancer in males. Bone metastases in PCa indicate poor prognosis and the major cause of pain and death. Early diagnosis of metastases is important in PCa management. Prostate specific antigen (PSA) velocity was used to predict overall survival and metastasis-free survival. However, this test should be conducted 2 times, for at least 4 weeks apart. Therefore, a cross-sectional test with higher positive probability value is needed. This study aimed to compare PSA density (PSAD) and PSA level to evaluate patients at risk of bone metastases in Yogyakarta, Indonesia. Aretrospective study with a total subject of 106 patients with (n = 31) and without (n = 75) bone metastases were analyzed. The initial PSA measurement, as well as bone scan and prostate volume, were evaluated in all patients. Bone survey found to be positive in 31/106 (29.2%) patients. The total of 50(47.2%), 10(9.4%) and 46(43.4%) patients had PSA level <50, 50-100 and >100ng/mL, respectively. Furthermore, receiver operating characteristic (ROC) area under the curve of PSAD (0.75) was higher that that ofPSA (0.65).PSAD more than 0.15 indicated sensitivity of 93% and specificity of 38%, while PSA more than 20 ng/mL shown sensitivity 82% and specificity 21%. In conclusion, PSAD level more than 0.15 shows high sensitivity and specificity in causing potential skeletal metastases. Using this PSAD cut-off value, unnecessary investigation canbe avoided.

Prostat cancer profile in Dr. Sardjito General Hospital Yogyakarta Yurisal Akhmad Dany; Ahmad Zulfan Hendri; Indrawarman Soerohardjo
Journal of the Medical Sciences (Berkala Ilmu Kedokteran) Vol 53, No 3 (2021)
Publisher : Journal of the Medical Sciences (Berkala Ilmu Kedokteran)

Prostate cancer is the fourth most common type of non-skin malignancy in male malignancies. In Indonesia, the definitive data are unreported, however, Globocan reported prostate cancer in 5th place in 2018. Early diagnosis and treatment of this cancer are associated with reduced mortality rates. This study aimed to investigate the profile of prostate cancer in Dr. Sardjito General Hospital, Yogyakarta, Indonesia. A retrospective study involving a total of 90 prostate cancer patients who underwent follow-up care at Dr. Sardjito General Hospital, Yogyakarta in the period of 2015 to 2020 was conducted. Data of the patients from their medical records consisted of age, gender, prostate volume, PSA level, testosterone level, hydronephrosis, TURP history, histopathology results, Gleason scores, ISUP grade, and staging TNM were collected. The average of patients age was 67 ±10.4 y.o. where 22 (24.4%) patients aged < 60 y.o., 34 (37.8%) patients aged 61-70 y.o. and 34 (37.8%) patients aged >70 y.o. Almost of all patients (87 patients or 97.8%) were diagnosed as adenocarcinoma. Most of patients (73 patients or 81.4%) had prostate volume (TAUS) > 30 cm3 with the median at diagnosis was 51 cm3 (38.3 – 104.4). Furthermore, the median of PSA for diagnosis was 234.4 (94.4 – 1720.3) ng/mL and the median of testosterone level at diagnosis was 317 (10 - 384) ng/dL. In conclusion, most patients with prostate cancer are identified as adenocarcinoma with metastatic stage. In general, the prostate cancer patients age more than 61 years old with prostate volume (TAUS) > 30 cm3. In addition, prostate volume and testosterone level can be routinely used as initial screening and periodic assessment to evaluate prognosis and disease progression.

Co-Authors . Zulfan Ahmad Zulfan Ahmad Zulfan Hendri Alharsya Franklyn Ruckle Andy Zulfiqqar Andy Zulfiqqar Brodjonegoro, Sakti R Danarto, Raden Didik Setyo Heriyanto Ery Kus Dwianingsih Frannata, Lucky H R Danarto Hariwibowo, Rinto Hendri, Ahmad Z Hendri, Ahmad Z. Indah S. Widyahening Indra Bayu Nugroho, Indra Bayu Irzan, Muhammad Anwar Krisna, Muhammad Sidharta Lydia Kristianti Muhammad Puteh Mauny Nur Rasyid Ponco Birowo Prahara Yuri Prakoso, Ragil Unggul Prawito Singodimedjo Prayogo, Dwi Raden Danarto Risan, Muhammad Sabdo Waloejo Sangundo, Muhammad Faham Soelatin Winarno Sumadi Lukman Anwar Yurisal Akhmad Dany Yurisal Akhmad Dany Zulfikar Ali, Zulfikar Zulfiqqar, Andy

Title Search

Found 3 Documents Search Journal : Journal of the Medical Sciences (Berkala Ilmu Kedokteran)

Abstract

Abstract

Abstract

Title

Found 3 Documents
Search
Journal : Journal of the Medical Sciences (Berkala Ilmu Kedokteran)